2022-503027-10-00招募中2 期
A randomized, double-blind, placebo-controlled, phase I/II trial of multi-donor fecal microbiota transfer for maintenance of Remission after Induction treatment with Exclusive Enteral Nutrition (EEN) in CroHn’s disease (EEN-RICH study)
Klinikum Der Universitat Munchen AöR4 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2023年7月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
- 试验地点
- 4
- 主要终点
- Incidence and severity of adverse events and serious adverse events in multi-donor-FMT-group compared to placebo
研究概览
简要总结
The aim of the trial is to assess safety, feasibility and efficacy of multi-donor FMT via administration of INTESTIFIX 001 FMT capsules in children and adults with Crohn´s disease. Primary objective: To evaluate the safety of multi-donor FMT for maintenance of remission after induction treatment with EEN in CD (week 0 to 32)
研究设计
- 分配方式
- Not Applicable
- 主要目的
- Observation period
- 盲法
- None
入排标准
- 年龄范围
- 0 years 至 64 years（0-17 Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Provision of signed and dated, written informed consent form prior to any study specific procedures, sampling, and analyses. For children: Written informed consent of both parents (legal guardians) and oral/written assent of patient due to age specific information.
- •Have negative stool results for enteric pathogens. Stool studies must include a stool culture and Clostridioides difficile toxin assay (C. difficile toxin/GDH with reflex to PCR testing). These must be performed during first four weeks of EEN run-in period or the current episode of disease exacerbation as long as the stool studies were performed within 2 months prior to study enrollment
- •Women of childbearing potential who are sexually active with opposite partners have to perform adequate contraception with a combination of a highly effective method of birth control and additional barrier contraception. [Highly effective method of birth control is defined as those, alone or in combination, that result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly for the entire study duration: combined (oestrogen and gestagen) oral contraceptives, hormone implants, hormone injectables, or hormone containing intrauterine device that needed to be in place for a period of at least 2 months prior to screening. Additional barrier contraception (at least the following methods are allowed: condom of the male, diaphragm with spermicide, portio cap with spermicide) has to be used for the duration of the trial, defined as from the time of screening to at least 90 days after Visit DB12 of the double-blind treatment phase. A single barrier method is not acceptable. Women of non-childbearing potential can be included if menstruation has not yet started, women are surgically sterile (documented complete hysterectomy or bi-tubal ligations) or post-menopausal >1 year.]
- •Men of reproductive potential must use condoms. In addition, the female partner should also be on a safe hormonal contraception (e.g. combined oral contraceptives, hormone implants, hormone injectables or hormone containing intrauterine device) or use a barrier contraception (e.g. intrauterine device, diaphragm or portio cap with spermicide), if she is of childbearing potential.
- •Subjects / legan guardians (parents) with knowledge of language and the ability to understand and to follow the study protocol mentally, including following study instructions (e.g. willingness to provide fecal samples during the visits and follow-up period). Subjects are likely to attend and complete all required visits.
- •Males and females 8 to 45 years of age with a body weight of ≥20 kg
- •Confirmation of Crohn’s disease active ileitis, colitis, or ileocolitis, confirmed at any time in the past by endoscopy and histology. Histology may be deferred for newly diagnosed patients until EEN2 (visit at week -4).
- •Ability to swallow IMP INTESTIFIX 001/placebo
- •Mild to moderate disease activity (wPCDAI 12.5-57.5 or CDAI 150-450) or milder disease activity with elevated fecal calprotectin > 250 mg/L prior to start of EEN.
- •Clinical response to EEN (EEN2, visit at week -4)
- •Receiving either no treatment or the listed treatment options with: a. Oral 5-aminosalicylic acid (5-ASA) compounds: stable or discontinued for ≥4 weeks prior to EEN3 (visit at week -1). The dose must be stable until OBS
- •b. Methotrexate (MTX): ≥4 weeks from initiation and on a stable dose prior to EEN3 (visit at week -1). The dose must be stable until OBS
- •c. 6-mercaptopurine (6-MP) or azathioprine (AZA): ≥12 weeks from initiation and on a stable dose for ≥4 weeks prior to EEN3 (visit at week -1). The dose must be stable until OBS
- •d. Biologic (e.g. TNF antagonists, vedolizumab, ustekinumab, risankizumab, mirikizumab): ≥16 weeks from initiation and on a stable dose prior to EEN3 (visit at week -1). The dose must be stable until OBS
- •Combination treatment of biologic with immuno-modulator (6-MP, AZA or MTX) is allowed, as described in b or c; e. JAK inhibitor (e.g. Upadacitinib): ≥16 weeks from initiation and on a stable dose prior to EEN3 (visit at week-1). The dose must be stable until OBS
- •f. Oral or IV corticosteroids or budesonide or beclomethasone dipropionate or rectal corticosteroids: discontinued for ≥2 weeks prior to EEN3 (visit at week -1)
- •Steroid-free clinical remission (wPCDAI or CDAI) after at least 6 weeks of EEN (EEN3, visit at week -1)
排除标准
- •Subject who is unable to understand the nature, scope, significance and consequences of this clinical trial
- •Patients with any malignancy or history of malignancy (excluding non-melanoma skin cancer)
- •Participants with clinically significant infections currently or within 3 months prior to baseline (eg, those requiring hospitalization or parenteral antimicrobial therapy or opportunistic infections)
- •Current (to be excluded by pregnancy test) or planned pregnancy or nursing women
- •The use of antibiotics or probiotics prescribed in the last 4 weeks prior to EEN
- •Previous EEN therapy without clinical efficacy or intolerance to Modulen IBD® (Nestlé Health Science).
- •Current combination therapy with dual biologics or treatment with Tofacitinib, Filgotinib, Rituximab, Alemtuzumab, Cyclosporine A, Tacrolimus, Sirolimus, Mycophenolat mofetil.
- •Subjects with an existing immune deficiency (i.e., SCID – severe combined immune deficiency, cellular or humoral immune deficiency)
- •The use of fecal microbiota transfer in the last 16 weeks prior to EEN3
- •Known history of hypersensitivity or allergies to the investigational capsule coating substances or to any compound of the FMT product/excipients.
- •Anemia with hemglobin <8 g/dl, white blood cells <2500/µl, neutrophils <1500/µl, platelets <100.000/µl, elevated liver enzymes (>3-times ULN), elevate serum creatinine;
- •Active/ongoing enterocutaneous, enterovesical, enterovaginal or enteroenteric fistula or symptomatic bowel strictures
- •Fistulizing perianal disease, which is not in clinical remission (e.g. seton allowed)
- •Active perianal or intraabdominal abcesses or other complications requiring surgical treatment
- •Prior intestinal resection, presence of stoma
- •Simultaneously participation in another clinical trial involving an investigational medicinal product or treatment with previous therapies (intended to be discontinued prior to study participation) within 30 days or 5 half-lives of the drug, whichever is longer, prior to informed consent. In case of previous biologic treatment, a shorter washout duration is acceptable, if undecetable drug levels of the biologic can be demonstrated.
- •Subjects with a physical (such as renal insufficiency, hepatitis, respiratory insufficiency, heart failure) or psychiatric condition which at the investigator’s discretion may put the subject at risk, may confound the trial results, or may interfere with the subject’s participation in this clinical trial
结局指标
主要结局
Incidence and severity of adverse events and serious adverse events in multi-donor-FMT-group compared to placebo
Incidence and severity of adverse events and serious adverse events in multi-donor-FMT-group compared to placebo
Summary of adjudicated safety events (e.g., opportunistic infection)
Summary of adjudicated safety events (e.g., opportunistic infection)
次要结局
- 1. To evaluate the feasibility of multi-donor FMT for maintenance of remission after induction treatment with EEN in CD (week -8 to 32) a.) Rate of recruitment of patients
- 1. To evaluate the feasibility of multi-donor FMT for maintenance of remission after induction treatment with EEN in CD (week -8 to 32) b.) Study withdrawal rates
- 1. To evaluate the feasibility of multi-donor FMT for maintenance of remission after induction treatment with EEN in CD (week -8 to 32) c) Adherence rate to EEN as determined by the proportion of patients with undetectable fecal gluten immunogenic peptides (GIP)
- 1. To evaluate the feasibility of multi-donor FMT for maintenance of remission after induction treatment with EEN in CD (week -8 to 32) d.) Proportion of patients having taken all capsules during the intervention period
- 1. To evaluate the feasibility of multi-donor FMT for maintenance of remission after induction treatment with EEN in CD (week -8 to 32) e) Difference between the number of biosamples collected and the total number of biosamples scheduled per patient as a marker for completeness of sample collection
- 2. To evaluate overall clinical efficacy of multi-donor FMT a. Difference in fecal calprotectin levels between week 0 and week 8 in multi-donor FMT compared to placebo
- 2. To evaluate overall clinical efficacy of multi-donor FMT b) Difference in C-reactive protein (CRP) levels between baseline (week 0) and week 8 in multi-donor FMT compared to placebo
- 2. To evaluate overall clinical efficacy of multi-donor FMT c) Change in CRP and fecal calprotectin levels over time (multi-donor FMT compared to placebo) (week -8 to 32)
- 2. To evaluate overall clinical efficacy of multi-donor FMT d) Relapse-free survival time (multi-donor FMT compared to placebo) (week 0 to 32)
- 2. To evaluate overall clinical efficacy of multi-donor FMT e) Clinical remission by physician global assessment at weeks 0, 4, 8, 12, 16, 24 and 32 (multi-donor FMT compared to placebo)
- 2. To evaluate overall clinical efficacy of multi-donor FMT f) Clinical remission by PCDAI and wPCDAI (children) / CDAI (adults) score at weeks 0, 4, 8, 12, 16, 24 and 32 (multi-donor FMT compared to placebo)
- 2. To evaluate overall clinical efficacy of multi-donor FMT g) Change from baseline (week -8) in PCDAI, shPCDAI and wPCDAI (children) / CDAI and HBI (adults) over time (multi-donor FMT compared to placebo)
- 2. To evaluate overall clinical efficacy of multi-donor FMT h) Response by intestinal ultrasound (IUS) at weeks 0, 4, 8, 16 and 32 (multi-donor FMT compared to placebo) in patients with increased bowel wall thickness (BWT) before EEN (week -8).
- 2. To evaluate overall clinical efficacy of multi-donor FMT i) Remission by IUS at weeks 0, 4, 8, 16 and 32 (multi-donor FMT compared to placebo).
- 2. To evaluate overall clinical efficacy of multi-donor FMT j) Change from baseline (week -8) in IUS parameters over time (multi-donor FMT compared to placebo).
- 2. To evaluate overall clinical efficacy of multi-donor FMT k) Prediction of clinical recurrence based on change of IUS parameters over time.
- 3. To evaluate patient reported outcomes and quality of life (QoL) (week -8 to 32) a) Change from baseline (week -8) in QoL IMPACT-III scores at weeks 0, 4, 8, 16, 32 (multi-donor FMT compared to placebo)
- 3. To evaluate patient reported outcomes and quality of life (QoL) (week -8 to 32) b) Change from baseline (week -8) in QoL SIBDQ scores at weeks 0, 4, 8, 16, 32 (multi-donor FMT compared to placebo)
研究者
Study Team
Scientific
Klinikum Der Universitat Munchen AöR
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)NCT07300085Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)710
进行中（未招募）
2 期
Taldefgrobep Alfa in Adults With Overweight and ObesityObesityNCT07281495Biohaven Therapeutics Ltd.150
招募中
3 期
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's DiseaseNCT07298421Hoffmann-La Roche100
招募中
2 期
Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell LymphomaNCT07285590Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea50
招募中
2 期
A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and PharmacokineticsNCT07260500Changchun GeneScience Pharmaceutical Co., Ltd.72